ClinicalTrials.Veeva

Menu
T

Total Skin and Beauty Dermatology Center | Birmingham, AL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986165
Risankizumab
CTP-543
Deucravacitinib
Amlitelimab
IDP-110
BOTOX
HTU-520
LIPO-202
Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 21 total trials

A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence (MMP US P3 416)

The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower fac...

Active, not recruiting
Masseter Muscle Prominence
Drug: Placebo
Drug: BOTOX

This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and saf...

Active, not recruiting
Alopecia Areata
Drug: Placebo
Drug: Amlitelimab

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Upadacitinib

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Active, not recruiting
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

The main purpose of this study is to evaluate the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in participants who have bee...

Active, not recruiting
Psoriasis
Drug: Placebo
Drug: BMS-986165

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair l...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Deuruxolitinib

Trial sponsors

AbbVie logo
Bristol-Myers Squibb (BMS) logo
S
Astellas logo
Concert Pharmaceuticals logo
D
E
Genentech logo
H
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems